Rodríguez AM, Rodríguez WF

Language: Spanish
References: 22
Page: 281-283
PDF size: 296.04 Kb.

ABSTRACT

Thrombophilia, protrombotic or hypercoagulability state refer to any situation in which there is a possibility to onset the formation of a blood clot by the interaction of diverse factors, in abnormal or inappropriate conditions. The mechanisms implied can lead to the formation of a thrombus and therefore to arterial or venous occlusion. Even though there can be many different etiologies, predisposing and triggering factors, in all of the cases there is an interaction between inherited and acquired factors. This gives great importance to the individualized determination of the protrombotic risk, identifying those factors or illnesses that predispose to thrombosis complementing with laboratories in patients who are known to have had previous thrombotic events or genetic predisposition. Determining the protrombotic risk is useful and fundamental in establishing early and adequate management, reducing the probabilities of developing further complications such as thrombosis and strokes.

REFERENCES

1. Mankovsky B, Ziegler D. Stroke in patients with diabetes mellitus. Diabetes Metab Res Rev 2004; 20: 268-87.

2. Sacco RL, Benjamin EJ, Broderick JP. Risk factores panel –American Heart Association Prevention Conference IV. Stroke 1997; 28: 1507-17.

3. Principales causas de mortalidad general 2001-2004. www. salud.gob.mx.

4. Principales causas de egresos hospitalario 2001-2004. www.salud.gob.mx.

5. Hans-Joachim GS, Sven Gutsche, Sabine Brücker, Peter Bucsky and Hogo A Katus. Antiphospolipid Antibodies in Children without and in Adults with and without Thrombophilia. Thrombosis Research 98; 2000:241-247

6. Pabinger I. Trombophilia and its impact on pregnancy. Thrombosis Research (2009) 123 Suppl.3, 16-21.

7. B.Brenner. Thrombophilia and pregnancy. Hematology, 2005; 10 Suppl 1: 186-189

8. Olivia Wu, Robertson L, Langhore P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. Thromb Haemost 2005; 94: 17-25.

9. Shannon MB. Management of Pregnant Women with Thrombophilia or a History of Venosus Thromboenmbolism. Hematology 2007; 143-150.

10. Falanga A, Thrombophilia in Cancer.Seminars in Thrombosis and Hemostasis 2005, 31:1: 104-110

11. Natanel Horowitz, Benjamin Brenner. Thrombophilia and Cancer. Pathophysiol Haemost Thromb 2007-08;36:131-136.

12. Rosovsky RP, Kuter D. Catheter- Related Thrombosis in Cancer Patients: Pathophysiology, Diagnosis, and Management. Hematol Oncol Clin N Am 19 (2005) 183-202.

13. Hirmerova J, Liska V, Mirka H, Chudacek Z, Treska V. Portal and mesenteric vein thromboses in a in a patient with prothrombin G20210 mutation, elevated lipoprotein (a), and high factor VIII. Clin Appl Thromb Hemost 2008 oct; 14(4):481-5. Epub 2007 Dec 26.

14. Ruiz-Arguelles GJ, Lopez-Martinez B; Cruz-Cruz D, Esparza-Silva L. Reyes-Aulis MB. Primary thrombophilia in Mexico III: A prospective study of the sticky platelet syndrome. Clin Appl Thromb Hemost 2002 jul;8(3):273-7.

15. Mosesson MW. Dysfibrinogenemia and thrombosis. Semi Thromb Hemost 1999; 25(3):311-319.

16. Uri Seligsohn, M.D, and Aharon Lubetsky, M.d. Genetic Susceptibility to Venous Thrombosis. N Engl J Med 2001; 344 (16) 1222-1230.

17. Ray Jg, Kearon C, Yi Q, et al,: Hemocysteine lowering therapy and risk for venous thomboembolism a randomized trial. Ann Internal Med 2007, 146:761-767.

18. D´Angelo A, Fermo I, Viganó D´Angelo S, Thrombophilia, Homocystinuria, and Mutation of the Factor V Gene. N Engl J Med 1996; 335:289-290

19. Ross R, Glomset JA. The pathogenesis of aterosclerosis. N Engl J Med 1976; 295: 369-377.

20. Ross R. The pathogensis of atherosclerosis-an update. N Engl J Med 1986; 314

21. Abreham Majluf Cruz, García Chávez J, Martínez Murillo C. Enfermedad tromboembólica venosa. Cap 1 pag.27-40.

22. Emmanuel JF, McDonald D, Lippi G. Laboratory Investigation of Thrombophilia: The Good, the Bad, and the Ugly. Semin Thromb Hemost 2009; 35(7); 695-709.